PFE
NYSE · Pharmaceuticals
Pfizer Inc.
$27.66
+0.02 (+0.07%)
PFE News30 articles
Pfizer Stock Hits 52-Week High at 10x Forward Earnings
Pfizer shares climbed 1.7% to $29.04, hitting a 52-week high, as the stock trades at 10x projected 2026 earnings, with a 5.9% dividend yield.
Pfizer's Core Growth Offsets COVID Decline, but $4B Forecast Raises Doubts
Pfizer (PFE) shares edged down 0.2% as Q2 revenue grew 3% to $15B, but a lowered COVID forecast to $4B raises questions about achieving 5% core growth.
Novavax Dips Slightly After Nuvaxovid Gains Approval in US, EU, Japan
Novavax shares slipped 0.6% to $9.00 after regulatory approvals for its updated vaccine in the US, EU, and Japan. The company now relies on partners like Sanofi for commercialization, with royalties expected but not yet in guidance.
XLV Retreats from Record as Mid-Sized Health Care Names Lag
XLV hit a record $169.71 before closing lower, lagging the S&P 500 by 0.74 points. Weakness among smaller health care holdings offset gains in top components.
Pfizer Stock Surges 7% on Q2 Beat, Offering 6.4% Dividend Yield
Pfizer shares gained 7% last week, beating the S&P 500, after Q2 adjusted EPS topped consensus by 13.2%. The stock's 6.43% yield exceeds analyst price target upside.
J&J Shares Hold Ground Despite 5.5% EPS Guidance Cut
Johnson & Johnson (NYSE:JNJ) closed at $259.24 on Friday, up 0.9%, despite a 5.5% cut to its 2026 adjusted EPS guidance. Investors appear to view the dilution as pipeline investment.
Pfizer Stock Rises 7% as Non-COVID Drugs Offset Pandemic Revenue Decline
Pfizer shares rose 7% last week, driven by strong performance from Eliquis and other key drugs that offset declining COVID product sales.
Dividend Stocks' Appeal Wanes Despite Fed Pause Hopes
Fed rate hike odds fell to 43.9% after July payrolls declined, but dividend stocks' yield premium over Treasuries remains thin, offering little cushion.
Pfizer Stock Rises as Core Drug Growth Offsets COVID Decline
Pfizer (PFE) shares rose 0.9% after Q2 results beat estimates, with non-COVID drug growth offsetting a steep decline in COVID product sales.
Pfizer Stock Rises as Non-COVID Drugs Offset Pandemic Revenue Slump
Pfizer's Q2 beat estimates as four growth brands offset COVID revenue declines. Shares rose 1.48% premarket.
Pfizer Beats Q2 Forecasts, Raises 2026 Sales Outlook
Pfizer's Q2 results beat expectations, driven by strong performance of key drugs, leading to a modest increase in its 2026 revenue forecast.
Bristol Myers Squibb at Crossroads as AstraZeneca Merger Talks Surface
Bristol Myers Squibb shares rose 5.2% last week after strong Q2 earnings, but a reported $400B merger approach from AstraZeneca puts the stock in focus Monday.
Pfizer Stock Climbs Ahead of Q2 Earnings on Strong Eliquis Sales Signal
Pfizer shares gained 2% this week ahead of Q2 earnings, bolstered by partner Bristol Myers' strong Eliquis sales and raised 2026 outlook.
Alnylam Shares Tumble 28% After Slashing Amvuttra Revenue Forecast
Shares of Alnylam Pharmaceuticals fell 28% after the firm lowered its Amvuttra revenue outlook, erasing $10.9 billion in equity value.
Pfizer Stock Edges Up Ahead of Q2 Report; Dividend Sustainability in Focus
Pfizer (PFE) shares edged higher ahead of its Q2 earnings report, as investors scrutinize whether the company's 7% dividend is sustainable amid cash flow pressures.
OPKO Stock Jumps 8% After Q2 Beat, Nicoya Deal Lifts Outlook
OPKO Health shares jumped 8% after hours as Q2 revenue beat by $32.35 million, largely from Nicoya preferred shares. The company also raised its 2026 revenue outlook.
Pfizer Stock Dips 1.9% but Dividend Adjusts Decline
Pfizer ended Friday at $24.54, down 1.9% unadjusted, but dividend-adjusted returns fell just 0.16%. The FDA's priority review for Talzenna offers a key catalyst for Q4.
TrumpRx Expansion to 800+ Drugs Heightens Tariff Risk for Generic Makers
Generic drug stocks fell after Trump announced tariffs up to 200% on imports by 2029, as TrumpRx expands to over 800 medications with 79 brand deals.
Pfizer Gains 3.6% as Dividend Yield Attracts Income Investors
Pfizer (PFE) shares climbed 3.6% as its 6.9% dividend yield attracted income-focused investors, despite unchanged analyst estimates and a slight earnings forecast cut.
TrumpRx Program Shows Limited Big Pharma Impact
TrumpRx's 79 presidential deals cover just 10% of branded drugs from 17 pharma firms, far below the touted 800. Major drugs like Ibrance and Biktarvy are excluded, limiting investor risk.
Pfizer Stock Rises as Sanofi Files Patent Suit Over COVID Vaccine Revenue
Pfizer shares gained 2.35% as Sanofi's patent lawsuit over Comirnaty targets past revenue rather than current sales, with modest financial risk relative to cash reserves.
Pfizer's 7% Dividend Yield Attracts Income Seekers Amid Market Turmoil
Pfizer (PFE) added 1.28% in post-market trading Monday, outperforming the broader market as investors rotated into defensive stocks amid geopolitical tensions and a tech selloff.
Pfizer Gains FDA Nod for Padcev Combo, Yet Stock Remains Flat
Pfizer's Padcev/Keytruda combo gets FDA approval for bladder cancer, but the stock dipped 0.33%. Wall Street remains cautious about revenue impact.
Moderna Plunges 11% as EU Vaccine Deal Lacks Minimum Purchase Guarantee
Moderna stock dropped 11.3% after the EU's RSV vaccine deal lacked a minimum purchase commitment, adding to investor worries about sales and cash burn.
Ionis Plunges 23% After Wainua Misses Key Goal in Heart Disease Trial
Ionis stock tumbled 23% after Wainua missed its primary endpoint in a major heart disease trial, erasing $3.2 billion in market value. The setback shifts attention to the company's TRYNGOLZA launch.
Pfizer Stock Rebounds After HSBC Downgrade, Dividend Yield Nears 7%
Pfizer shares recover some losses after HSBC downgrades the stock to Hold, slashing its price target by $4 to $28, as the dividend yield remains near 7%.
Pfizer's Dividend Sustainability in Focus After HSBC Downgrade
Pfizer shares slid after HSBC downgraded the stock, turning investor attention to the sustainability of its 7.3% dividend yield amid a payout ratio near 60% of adjusted EPS guidance.
Pfizer's 7% Yield Beckons as Stock Lingers Near $24
Pfizer (PFE) trades near $24 with a 7.1% yield after a flat week. The company's Q1 dividends rivaled R&D spending, underscoring a focus on shareholder returns.
Pfizer's 7% Yield Attracts Income Seekers as Pharma Sector Stalls
Pfizer shares edged up 1.84% to $24.32, offering a 7.07% yield, but the stock has declined 14.12% over the past three months amid a sluggish pharmaceutical sector.
Moderna Surges 10% as Flu Vaccine Hopes Add $2.9B to Market Cap
Moderna shares surged over 10% in after-hours trading, adding roughly $2.9 billion in market value as investor enthusiasm for its flu vaccine pipeline continues to build.